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Effectiveness and cost-effectiveness of a nurse-delivered 
intervention to improve adherence to treatment for HIV: 
a pragmatic, multicentre, open-label, randomised clinical trial
Marijn de Bruin, Edwin J M Oberjé, Wolfgang Viechtbauer, Hans-Erik Nobel, Mickaël Hiligsmann, Cees van Nieuwkoop, Jan Veenstra, 
Frank J Pijnappel, Frank P Kroon, Laura van Zonneveld, Paul H P Groeneveld, Marjolein van Broekhuizen, Silvia M A A Evers, Jan M Prins
Summary
Background No high-quality trials have provided evidence of effectiveness and cost-effectiveness of HIV treatment 
adherence intervention strategies. We therefore examined the effectiveness and cost-effectiveness of the Adherence 
Improving self-Management Strategy (AIMS) compared with treatment as usual.   
Methods We did a pragmatic, multicentre, open-label, randomised controlled trial in seven HIV clinics at academic 
and non-academic hospitals in the Netherlands. Eligible participants were patients with HIV who were either 
treatment experienced (ie, with ≥9 months on combination antiretroviral therapy [ART] and at risk of viral rebound) 
or treatment-naive patients initiating their first combination ART regimen. We randomly assigned participants (1:1) 
to either AIMS or treatment as usual (ie, containing a range of common adherence intervention strategies) using a 
computer-generated randomisation table. Randomisation was stratified by treatment experience (experienced vs 
naive) and included block randomisation at nurse level with randomly ordered blocks of size four, six, and eight. 
21 HIV nurses from the participating clinics received three training sessions of 6 h each (18 h in total) on AIMS and 
a 1·5 h booster training session at the clinic (two to three nurses per session) after each nurse had seen two to three 
patients. AIMS was delivered by nurses during routine clinic visits. We did mixed-effects, intent-to-treat analyses to 
examine treatment effects on the primary outcome of log10 viral load collected at months 5, 10, and 15. The viral load 
results were exponentiated (with base 10) for easier interpretation. Using cohort data from 7347 Dutch patients with 
HIV to calculate the natural course of illness, we developed a lifetime Markov model to estimate the primary economic 
outcome of lifetime societal costs per quality-adjusted life-years (QALYs) gained. This trial is registered at ClinicalTrials.
gov (number NCT01429142).
Findings We recruited participants between Sept 1, 2011, and April 2, 2013; the last patient completed the study on 
June 16, 2014. The intent-to-treat sample comprised 221 patients; 109 assigned to AIMS and 112 to treatment as usual. 
Across the three timepoints (months 5, 10, and 15), log viral load was 1·26 times higher (95% CI 1·04–1·52) in the 
treatment-as-usual group (estimated marginal mean 44·5 copies per mL [95% CI 35·5–55·9]) than in the AIMS group 
(estimated marginal mean 35·4 copies per mL [29·9–42·0]). Additionally, AIMS was cost-effective (ie, dominant: cheaper 
and more effective) since it reduced lifetime societal costs by €592 per patient and increased QALYs by 0·034 per patient.
Interpretation Findings from preparatory studies have shown that AIMS is acceptable, feasible to deliver in routine 
care, and has reproducible effects on medication adherence. In this study, AIMS reduced viral load, increased QALYs, 
and saved resources. Implementation of AIMS in routine clinical HIV care is therefore recommended.
Funding Netherlands Organisation for Health Research and Development.
Introduction
Efficacious drugs for the treatment of HIV/AIDS have 
been widely available in high-income countries since 
1996, and are becoming increasingly available in low-
income countries. The life expectancy of people with HIV 
using antiretroviral therapy (ART) is now almost identical 
to that of people without HIV.1 Moreover, the risk of HIV 
transmission is reduced considerably for successfully 
treated patients.2 However, despite a marked reduction in 
side-effects and complexity of combination ART regimens 
over the past two decades, suboptimum intake of drugs 
(faulty execution) and premature discontinuation (non-
persistence) of com bination ART continue to compromise 
treatment effectiveness.3 Non-adherence can lead to poor 
patient outcomes, the development of drug-resistant 
virus, fewer treatment options because of drug resistance, 
and increased transmission risks of viral strains, 
including resistant ones.4–9 Hence, supporting patients’ 
adherence is an important objective from a patient and 
public health perspective, and essential for achieving the 
UNAIDS 90-90-90 targets.10
For the long-term success of combination ART and its 
consequent effect on the spread of HIV, suboptimal 
adherence has to be addressed before virological failure 
occurs. Although results from meta-regression analyses 
suggest that the quality of adherence support provided to 
patients has a large influence on viral suppression 
rates,11,12 little direct experimental evidence shows that 
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adherence interventions have a sustained effect on 
adherence and—more importantly—on viral loads and 
CD4 cell counts.13,14 A Cochrane review did not identify 
any low risk of bias trials of HIV adherence interventions 
in high-income countries that provided evidence of 
intervention effects on adherence and clinical outcomes 
such as viral load. Two trials were identified in low-
income countries, the results from which showed 
promising effects on viral load.15 Moreover, no evidence is 
available that shows effective HIV treatment adherence 
inter ventions yield benefits for society in terms of cost-
effectiveness.16 Our updated search of the scientific 
literature did not yield additional evidence.
In 2003, we developed the Adherence Improving self-
Management Strategy (AIMS), based on empirical 
literature, behavioural theories, and input from health-
care professionals and patients.17 AIMS is a nurse-
delivered, one-on-one behavioural intervention that 
incorporates adherence feedback from electronic 
medication monitors (Medication Event Monitoring 
System [MEMS]-caps; an electronic pill-bottle cap that 
registers date and time of bottle opening) and is designed 
to fit into routine clinic visits. After a successful pilot 
study17 that highlighted its acceptability, feasibility, and 
effects on adherence, we did a single-centre randomised 
controlled trial with treatment-experienced patients.18 
Although powered to detect an effect on adherence (the 
primary outcome), this trial also provided tentative 
evidence of improved viral suppression rates (a secondary 
outcome). However, this trial had a homogeneous patient 
group and a short follow-up of 7 months. Showing 
clinically relevant effects on viral load in a high-quality 
pragmatic trial with a long follow-up, and a heterogeneous 
group of patients and HIV clinics, could provide 
conclusive evidence that AIMS is effective. Moreover, 
showing that AIMS is also cost-effective would be 
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Research in context
Evidence before this study
We searched for effectiveness and cost-effectiveness evidence 
from trials done in high-income countries, with at least 
12 months follow-up including a clinical outcome that 
focused on adult HIV-infected patients. Interventions had to 
promote autonomous behaviour (ie, directly observed 
therapy interventions were excluded) and treatment 
simplification studies (eg, once-daily versus twice-daily 
medication) were excluded. For evidence on effectiveness of 
the interventions we searched MEDLINE, PsycINFO, and Embase 
with no language restrictions for articles published between 
January, 2013, and October, 2016, using the terms (“HIV” or 
“HAART” or “cART” or “Antiretroviral”) and (“adherence” or 
“compliance” or “persistence” or “concordance”) and (“viral 
load” or “virologic failure” or “CD4”) in the title or abstract, and 
(“random*” or “clinical trial”) in all text, and (“2013” or “2014” 
or “2015” or “2016”) in the year. We identified 529 unique 
titles, of which 27 assessed an adherence intervention. Only one 
was an eligible trial, assessing the Managed Problem Solving 
(MaPS) intervention, which noted that MaPS improved 
adherence. A particular strength of the trial was the high 
consent rate; possible weaknesses were differential attrition 
and a missing data imputation method that deemed missing 
data to equal treatment failure. No cost-effectiveness analysis 
was reported. For evidence on cost-effectiveness of adherence 
interventions, we searched the same databases and date range 
as above with the terms (“HIV” or “HAART” or “cART” or 
“Antiretroviral”) and (“adherence” or “compliance” or 
“persistence” or “concordance”) and (“Cost Analysis” or “Cost 
Effectiveness” or “Cost Benefit” or “Cost Utility” or “Cost 
Minimi#ation” or “Economic Evaluation”) in the title or abstract, 
and (“2013” or “2014” or “2015” or “2016”) in the year. 
We identified 137 unique titles and abstracts, of which only one 
was an eligible study that reported the cost-effectiveness of a 
computer-delivered intervention to promote adherence to HIV 
medication (FL, USA). This assessment was, however, based on 
effectiveness data from a subgroup analysis in a short-term 
intervention feasibility study. Further limitations were that the 
effectiveness data was derived from self-reported adherence and 
did not line up with the effectiveness input in the economic 
model. Thus, these searches did not identify any adherence 
interventions from high-quality, long-term trials, and economic 
assessment that provided evidence of effectiveness and 
cost-effectiveness.
Added value of this study
To our knowledge, this multicentre, randomised controlled trial 
and economic model is the first to show that our adherence 
intervention Adherence Improving self-Management Strategy 
(AIMS) produced meaningful effects on viral load and was 
cost-effective in a high-resource setting, compared with 
treatment as usual. The findings from the study showed that 
HIV treatment adherence interventions can increase 
quality-adjusted life-years (QALYs) while saving resources, even 
when compared with medium-to-high-quality 
treatment-as-usual adherence support. Moreover, AIMS 
required few resources because it has been adapted to fit in 
routine HIV clinic services, which should facilitate 
implementation in routine care.
Implications of all the available evidence
HIV treatment adherence interventions, such as AIMS, can 
benefit patients, even in high-resource settings, and lead to 
gains in QALYs while saving resources. AIMS seems at present 
to be the only adherence intervention for which the effects 
have been replicated in consecutive trials. The economic 
evaluation also provided robust evidence on cost-effectiveness. 
Implementation of AIMS in routine clinical care is therefore 
recommended.
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important for policy makers, as well as for adherence 
intervention research generally, given the scant evidence 
of the economic benefits of adherence interventions.
Effective HIV treatment adherence interventions 
should benefit patient and public health, and reduce 
health-care expenditures; yet, experimental evidence of 
these benefits is scarce. This report describes findings 
from our study that assessed the effectiveness of AIMS, 
and the results of a Markov model assessing the cost-
effectiveness of AIMS over a lifetime horizon.
Methods
Study design and participants
The protocol for this study has been published19 and a 
separate article has been published on the strategies used 
for reducing the risk of bias in this trial20 (the appendix 
includes a table summarising the risk of bias rationale in 
this article). We did a pragmatic, multicentre, open-label, 
randomised controlled trial in seven HIV clinics at 
academic and non-academic hospitals in the Netherlands.
Eligible participants were patients with HIV who were 
either treatment-experienced (≥9 months on combination 
ART and at risk of viral rebound), or treatment-naive 
patients initiating their first combination ART regimen. 
At risk of viral rebound was determined on the basis of 
having at least one detectable viral load during the 
previous 3 years and suboptimal adherence during 
2 months baseline MEMS monitoring (<100% adherence 
for once-daily and ≤95% for twice-daily regimens). These 
criteria were based on analyses of data from a large HIV 
cohort including all registered HIV patients in the 
Netherlands,21 and from our previous trial.18 Exclusion 
criteria were: age less than 18 years, severe psychiatric 
disorders or other comorbidities precluding compliance 
with study procedures, pregnancy, plans to interrupt 
treatment in the next 14 months, life expectancy less than 
1 year, not able to communicate in English or Dutch, viral 
resistance to three or more antiretroviral drug classes, 
and about to initiate hepatitis C treatment. Eligible 
patients were approached by their treating physician or 
HIV nurse, and given information about the study 
verbally and in writing. All patients gave written informed 
consent. The trial was approved by the medical ethics 
committees of all participating hospitals. Given the 
absence of any patient safety risks according to the 
medical ethics committee that approved the trial, there 
was no data and safety monitoring board.
Randomisation and masking
We randomly assigned consenting participants (1:1) to 
either AIMS or treatment as usual (ie, containing a range 
of common adherence intervention strategies) using a 
computer-generated randomisation table. The resulting 
risk of contamination was kept low because key inter-
vention elements, such as MEMS feedback and all other 
intervention materials (panel) could only be accessed 
when a MEMS-cap of a patient in the intervention group 
was downloaded.20 Randomisation was stratified by 
treatment experience (experienced vs naive) and we used 
block randomisation (with randomly ordered blocks of 
size four, six, and eight to avoid predictability of 
assignment) to balance intervention and control patients 
over nurses. The randomisation table was computer-
generated by a statistician and treatment assignment was 
done automatically by software after nurses entered the 
details of consenting patients on a study website. Because 
masking to treatment assignment was not possible given 
the nature of the intervention, we developed a distraction 
strategy for drawing the attention of patients and health-
care providers away from the primary study aims. 
Specifically, we included a second research objective in 
the study (ie, to examine the content of, and patient 
satisfaction with, nursing care provided to patients 
treated for HIV), and the regular questionnaires that 
nurses and patients completed during the trial focused 
on this study aim, rather than on the comparison of 
AIMS versus treatment as usual.20 The statistician (WV) 
who did the analyses was masked to group assignment.
Procedures
21 HIV nurses from the seven participating clinics 
received three training sessions (6 h each, 18 h in total) 
on AIMS and on how to use the MEMS-caps and 
software. A 1·5-h booster session was delivered at each 
HIV clinic (two to three nurses per session) after each 
nurse had seen two to three patients. The first author 
(MdB) delivered the training and booster sessions. There 
was no additional support or advice in relation to the 
delivery of the intervention.
Details of patient demographic characteristics and 
treatment were obtained at baseline. Plasma viral load 
and CD4 cell counts were assessed at baseline and at 
approximately 5 months, 10 months, and 15 months as 
part of routine care. For treatment-initiating patients, the 
first follow-up measurement was planned slightly later at 
6 months, to allow their viral load to become undetectable. 
Treatment-experienced patients followed the usual 
4–5 months visit interval. The viral load assays used were 
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 
(Roche), Abbott m2000 RealTime HIV-1, and NucliSENS 
Easy Q HIV-1 v2.0 (Biomerieux), with lower detection 
limits varying from 20 to 75 copies per mL. The study was 
overpowered for detecting an effect on adherence. To 
avoid unnecessary study burden, we measured MEMS 
adherence in a randomly selected 50% of the control 
group patients. Since a subset of patients preferred using 
their own medication bottles over the MEMS-caps bottles 
(especially if MEMS-caps were used for monitoring only, 
as in the treatment-as-usual group),18,22 and because 
adherence was a secondary outcome, if randomised 
patients preferred further trial participation without 
MEMS monitoring, they were allowed to do so (appendix). 
The quality and quantity of treatment as usual 
adherence support provided to control groups in 
See Online for appendix
Articles
598 www.thelancet.com/infection   Vol 17   June 2017
Panel: Treatment-as-usual strategy versus the Adherence Improving self-Management Strategy (AIMS)
Materials used
Treatment as usual
•	 Patient	information	leaflet
AIMS
•	 Simple	graph	explaining	how	drug	concentrations	vary	
with adherence patterns, and affect treatment outcomes
•	 Seven	example	adherence	reports	from	electronic	
monitors ranging from excellent to poor adherence
•	 A	list	with	common	reasons	that	other	patients	have	given	
for achieving high adherence
•	 MEMS-cap	to	monitor	own	adherence	and	obtain	printed	
personal adherence reports
•	 Templates	for	action	plans	and	coping	plans
•	 Drop-down	lists	with	common	reasons	for	non-adherence	
and effective solutions for dealing with these problems
•	 Ruler	(1–10	scale)	to	score	own	confidence	in	improving	
adherence
•	 For	treatment-initiating	patients	only:	score	sheet	of	
five reasons for, and five concerns about, initiating 
treatment
Procedures
Treatment as usual
When the physician, nurse, and patient agreed that treatment 
should be initiated, typically the following activities were done 
to support adherence:
•	 Patients	were	given	a	verbal	explanation	of	how	the	
medication works and what the relation is between 
adherence, viral replication, and treatment outcomes. This 
explanation included risks (eg, viral resistance) and 
benefits (eg, a healthy immune system and being less 
infectious) of adherence and non-adherence. An 
information	leaflet	was	provided.
•	 Patients	were	given	an	explanation	of	how	to	take	the	
medication, how often, and at what dose.
•	 The	nurse	and	patient	discussed	when	it	was	best	for	each	
individual patient to take their medication (at what time 
and where, linking intake to daily routines or using 
reminder devices that can serve as cues)
•	 Patient	were	given	a	telephone	number	to	call	in	case	of	
difficulties (eg, occurrence of side-effects or difficulties with 
adherence)
•	 During	follow-up	visits:
•	 Patient	and	nurse	discussed	self-reported	adherence	
(and any problems) and tried to identify solutions that 
would work for that patient
•	 The	nurse	or	physician	asked	the	patient	about	any	
side-effects and discussed how to deal with them (if 
severe, a change of regimen is considered)
•	 Nurses	provided	feedback	on	viral	load	and	CD4	cell	
counts. If results were positive, this finding served to 
reinforce adherence. If results were negative, adherence 
problems or other causes (eg, drug resistance or drug 
interactions) were explored (appendix)
Management of side effects, feedback of clinical outcomes, 
and receiving a telephone number in case of difficulties was 
also part of the routine care for AIMS patients.
AIMS
Here we explained AIMS for treatment-experienced patients. 
The intervention at the first visit was slightly different for 
treatment-naive patients (appendix). 
Before the first AIMS intervention visit, patients used an electronic 
medication	monitor	for	4–8	weeks.	Data	were	downloaded	and	a	
website guided patients and nurses through the steps below. 
Tailoring of the intervention to the needs and abilities of each 
individual patient was a core component of each step.
•	 Similar	to	step	1	for	treatment	as	usual,	except	that	material	
1 was used to aid discussion and storage of information in 
long-term memory.
•	 Nurse	explained	seven	exemplar	MEMS-reports	using	
material 2 while linking patterns of adherence and 
non-adherence to the adherence-outcome information 
discussed in step 1. The patient selected one adherence 
report	reflecting	how	they	would	like	to	take	their	
medication (desired adherence level) and the nurse asked 
the patient to explain why this is important to them 
personally and in the long run (material 3).
•	 Patients’	own	MEMS-report	was	printed	(actual	adherence	
level; material 4) and compared with their desired 
adherence level. The nurse reinforced periods of good 
adherence and highlighted discrepancies (ie, where actual 
adherence was lower than desired).
•	 Patient	MEMS-report	was	used	to	identify	any	
non-adherence patterns, causes, and solutions. These were 
written down in coping plans (using an if…, then… format; 
materials 5 and 6).
•	 Patient	selected	an	adherence	goal	for	the	next	visit	using	
material 2 and scored their confidence in their ability to 
accomplish that goal (material 7). If confidence was low, the 
nurse explored whether important adherence barriers had 
been unaddressed or if their adherence goal should be 
approached incrementally.
•	 The	patient	was	offered	a	MEMS-view	cap	with	a	display	
showing how often the bottle had been opened that day (to 
facilitate adherence self-monitoring; material 4). Patient 
was given their printed adherence report and coping plan.
•	 Subsequent	intervention	sessions	were	mainly	repetitions	
of steps 3, 4, and 5. The aim was that patients reached their 
desired level of adherence during the first 5 months of the 
intervention, strived for behavioural maintenance during 
the next 5 months, followed by a follow-up of another 
5 months. Patients with many adherence difficulties could 
be seen more frequently.
Both the treatment-as-usual strategy and AIMS were delivered as part of routine care by 
trained HIV/AIDS nurses. The panel summarises the materials used and procedures for 
both strategies. A more comprehensive table including the behavioural-change objectives 
and techniques is in the appendix. MEMS=electronic medication monitors. 
AIMS=Adherence Improving self-Management Strategy.
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adherence trials varies between trials and impacts on 
effect sizes.11,12 We developed a minimally intrusive 
method for collecting treatment as usual data from 
participating nurses,23 and noted that treatment as usual 
in participating clinics ranged from medium to high 
quality when compared with meta-analyses on this 
topic.11,12 Treatment as usual was not standardised 
between clinics for the purpose of this trial, and reflected 
what patients receive in routine clinical care in the 
Netherlands. The panel shows details of the AIMS 
intervention and treatment as usual. 
Outcomes
The primary effectiveness outcome was defined as log10-
transformed plasma viral load (copies per mL) across the 
three follow-up timepoints (5, 10, and 15  months). The 
secondary effectiveness outcome was percentage 
adherence. Post-hoc outcomes were (1) treatment failure, 
defined as having a detectable viral load on two 
consecutive follow-up measurements; (2) CD4 cell counts 
(cells per µL); and (3) detectable versus undetectable viral 
loads, which was to be used as the primary outcome 
instead of log10 viral load if the skewed distribution of 
log10 viral load data would lead to violation of statistical 
model assumptions. Because model assumptions were 
not violated, this analysis was reported as post hoc.
Using cohort data from 7347 Dutch patients with HIV 
to calculate the natural course of illness, we developed a 
lifetime Markov model to estimate the primary economic 
outcome of lifetime societal costs (including health-care 
costs, productivity loss, HIV transmission costs, and 
intervention cost) per quality-adjusted life-years (QALYs) 
of AIMS versus treatment as usual.19 A trial-based 
economic assessment, which examined the short-term 
economic outcomes observed during the follow-up of the 
trial and therefore has another primary outcome (same 
trial number as this study), will be published separately.
Statistical analysis
The study was powered to detect an effect on plasma viral 
load, measured at three consecutive timepoints, while 
controlling for baseline viral load. A sample of 
230 randomised patients was required to obtain 
80% power to detect a significant intervention effect on 
viral load for at least one of three timepoints with α=0·05 
(two-sided), using a Bonferroni correction and assuming 
a maximum dropout of 10%.
The primary intent-to-treat analysis for log10 viral load 
used a mixed-effects (multilevel) model.24,25 A factor for 
timepoint (three levels, one for each follow-up measure-
ment at months 5, 10, and 15), group (two levels), and 
their interaction (testing for a between-group change 
during follow-up) were the primary variables of interest. 
In the absence of a time-by-group interaction, the overall 
intervention effect can be estimated by a between-group 
(marginal) contrast across the three follow-up timepoints. 
Baseline viral load and the stratification variable 
(treatment-experienced vs treatment-naive) were added to 
the model as covariates; as well as a four-level factor for 
ethnic group (white, sub-Saharan African, Caribbean, 
and others), as this is an important prognostic 
covariate.11,20 The viral load results were exponentiated 
(with base 10) for easier inter pretation. Undetectable 
viral loads (eg, <40 copies per mL) were replaced by the 
corresponding detection limit.
We also did: (1) a mixed-effects logistic regression 
model,25 using detectable versus undetectable viral load 
(based on the detection limit of each respective clinic). The 
detection limit value of each viral load test was added as an 
additional covariate; (2) a mixed-effects logistic regression 
model examining treatment failure, using the same 
covariates; and (3) a mixed-effects model examining the 
effects of the intervention on CD4 cell count, using the 
same model as for the primary viral load analysis, but with 
viral load replaced by CD4 values. No statistical analyses 
were done for adherence, because of substantial differences 
in the uptake of the MEMS monitoring between the study 
arms (eg, 52 [91%] of 57 treatment-naive patients assigned 
to AIMS vs 15 [54%] of 28 assigned to treatment as usual 
started the use of MEMS after randomisation).
Based on the fitted models, we also obtained marginal 
estimates of the specific means for the AIMS and 
treatment-as-usual groups (viral load and CD4 cell count 
analyses) and risks (detectable viral load and treatment 
failure analyses), using the median value at baseline for 
continuous covariates (ie, baseline viral load and 
detection limit) and the observed proportions at baseline 
for categorical covariates (ie, treatment-experienced vs 
treatment-naive, ethnic group, and detection status at 
baseline).
Analyses were done in R (version 3.1.2) using the nlme 
package,24 and Stata (version 13.1) using functions mixed 
and meqrlogit. The appendix shows additional details on 
the sample size calculation and statistical analyses.
Our Markov model was based on the Dutch guideline 
for health economic evaluations and international 
guidelines for modelling (ISPOR-SMDM guidelines).26 
In a Markov model, a cohort of patients is assumed to 
transit between health states. Based on the scientific 
literature8,27,28 and input from clinicians in the parti-
cipating clinics, 13 health states were identified: three 
CD4-cell count categories (0–200, 201–500, and >500 
cells per µL) combined with four viral load categories 
(0–50, 51–200, 201–1000, and >1000 copies per mL), and 
death. These health states capture the key changes in 
viral load and CD4 cell count associated with changes in 
costs, HIV transmission risk, and quality of life. Patients 
could change between health states every 6 months. All 
transitions between health states are possible except 
when a patient died. Hence, the Markov model was a 
matrix of 13 rows (current health status) and 13 columns 
(the health state patients move to; appendix).
Next, we calculated the 6-month transition probabilities 
of patients on treatment as usual moving between these 
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health states (the natural course of illness), and the 
health-care consumption in each health state over a 
6-month period. For this, we obtained a longitudinal 
dataset (2008–15) from the HIV Monitoring Foundation 
in the Netherlands. We used data from all registered 
Dutch HIV patients (n=7347) who were on treatment for 
at least 12 months, and had at least one detectable RNA 
viral load measurement (>50 copies per mL) in the past 
3 years (excluding the first 12 months of treatment), to 
approximate the inclusion criteria for treatment-
experienced patients in the trial. Excess mortality per 
health state was also derived from this cohort. Utility data 
(ie, quality of life) per health state were based on CD4 cell 
count and obtained from another cohort study.27 HIV 
transmission probabilities per health state based on viral 
load data were estimated by the lead author of an HIV 
transmission modelling study,8 and multiplied by the 
lifetime treatment costs for an HIV-infected patient.28 For 
the societal perspective, the model also included 
productivity losses per health state based on 600 question-
naires completed by 195 patients during the current trial. 
The appendix shows these transition probabilities, costs 
(health-care costs, HIV transmission costs, and 
productivity loss), and utilities per health state.
To assess the cost-effectiveness of AIMS, data were 
required on the intervention cost, as well as on the effects 
of AIMS on the transition probabilities during and after 
the intervention period. These effects were calculated 
from the trial data and expressed in relative risks (AIMS 
vs treatment as usual; appendix). For the AIMS 
intervention, these relative risks were then applied to the 
natural course of illness (appendix) over three 6-month 
cycles, which was the approximate duration of the trial. 
The cohort of patients receiving AIMS therefore had 
different probabilities of moving between health states 
than patients receiving treatment as usual, and therefore 
costs and outcomes were different.
To define the relative risks of AIMS, we did a base case 
and two additional scenarios. The base case (scenario 1) 
included all relative risks (AIMS vs treatment as usual) 
when at least five transitions occurred in the trial 
(appendix). Scenario 2 included all available relative risks 
irrespective of the number of transitions, whereas the 
more conservative scenario 3 included only relative risks 
with at least ten transitions. Within these three scenarios, 
we varied our assumptions about how long the effects of 
AIMS would last if delivery would be discontinued after 
the initial 18 months: (1) a linear decrease of the effects of 
AIMS to zero 18 months after intervention dis con-
tinuation; (2) no effect after AIMS discontinuation; and 
(3) AIMS effects fully sustained for another 18 months, 
and then to zero. A total of nine scenarios were therefore 
tested. We also did sensitivity analyses for a health-care 
perspective (ie, excluding productivity losses) and a time 
horizon of 10 years instead of lifetime.
For each scenario and sensitivity analysis, we estimated 
the societal costs and QALYs of AIMS compared with 
treatment as usual, and calculated the incremental cost-
effectiveness ratio (ICER) between AIMS and treatment 
as usual. The ICER expresses the additional cost of AIMS 
compared with treatment as usual to obtain one 
additional QALY. When an intervention is more effective 
and less costly, the intervention is said to be cost-saving. 
896 approached for participation
         286 treatment-naive
         610 treatment-experienced
370 signed informed consent
         113 treatment-naive
         257 treatment-experienced
224 randomised
         113 treatment-naive
         111 treatment-experienced
111 allocated to AIMS
109 intention-to-treat sample
108 at second follow-up
       1 died
       6 missing HIV RNA test
105 at third follow-up
      1 lost to follow-up
     2 died
      9 missing HIV RNA test
109 at first follow-up
       3 missing HIV RNA test
113 allocated to treatment as usual
112 intention-to-treat sample
110 at second follow-up
      1 lost to follow-up
       1 died
       5 missing HIV RNA test
108 at third follow-up
       2 lost to follow-up
       5 missing HIV RNA test
112 at first follow-up
       7 missing HIV RNA test
526 refused*
 183 MEMS too big or impractical
 103 fear for a disruption of daily intake
 96 not willing to participate in studies
 44 too much study burden
 27 not willing to sign consent form
48 other
33 topic of study too confronting
76 no reason given
146 excluded
 67 perfect adherer during baseline monitoring period
 74 withdrew consent after 2 months baseline monitoring
 5 lost to follow-up
3 excluded 
    1 ineligible patient not planning to start treatment (AIMS)
    1 died shortly after randomisation without any outcome data
(treatment as usual)
    1 incarcerated shortly after randomisation without any
        outcome data (AIMS)
Figure: Trial profile
* Not all patients were willing to disclose a reason for refusal and patients could provide more than one reason for 
refusing participation. 
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This trial is registered at ClinicalTrials.gov (number 
NCT01429142).
Data sharing
The data for the effectiveness analyses are available 
online (https://osf.io/wk8vm/). The data for the cost-
effectiveness analyses are in the appendix. 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility to 
submit for publication.
Results
Patient recruitment started on Sept 1, 2011, and was 
completed on April 2, 2013. The last patient completed 
the study on June 16, 2014. 224 patients were randomly 
assigned to treatment, which was slightly below the target 
of 230 but dropout was lower than anticipated (ten [4·5%] 
of 224 instead of 10%). The intent-to-treat sample was 
comprised of 221 patients, 109 assigned to AIMS and 112 
to treatment as usual (figure). One patient who was not 
planning to start with combination ART was accidentally 
randomly assigned, and two eligible patients (one in each 
arm) did not provide any outcome data, because soon 
after randomisation one died of a cardiovascular event, 
and the other was incarcerated in another country. 
Because these reasons were unrelated to group 
assignment or the dependent variable, team members 
(MdB, WV, and JMP) masked to group assignment 
concluded these were valid reasons for exclusion 
(Cochrane handbook 8.13 and 16.2).29
Most of the intent-to-treat sample was male and white, 
with a mean age of 44 years (SD 10·9) and a low to 
medium educational level (table 1). About half the 
participants were treatment-experienced and of those, 
37 (34%) of 109 had a detectable viral load at baseline, 
confirming that the at-risk selection criteria were useful 
(viral suppression rate in the general treatment-
experienced population in the Netherlands is 91%).30 In a 
logistic regression analysis, study participation was 
associated with being treatment-naive (p<0·0001), but 
study participation could not be predicted by sex, age, 
ethnic group, CD4 cell count, or viral load (p>0·5 for all).
Mean follow-up was 14·6 months (SD 2·7). The mean 
number of visits were 3·2 (SD 1·6) for treatment as usual 
and 3·2 (1·7) for AIMS. The mean number of days 
between randomisation and follow-up assessments  for 
treatment-experienced versus treatment-naive patients 
were 125 days (SD 44) versus 177 days (54) for the first 
follow-up, 270 days (76) versus 306 days (69) for the 
second, and 447 days (87) versus 454 days (83) for the 
third visit. 
The delivery of treatment as usual took on average 
18·8 min; AIMS delivery took on average 29·1 min 
(a difference of 10·3 min per visit, with a total of 35 min 
during the entire follow-up), during which adherence 
support and also other treatment-as-usual activities were 
delivered. 
AIMS patients received on average 85% of all planned 
intervention visits, during which 65% of all the intervention 
elements were delivered (recorded on the intervention 
website). The main reason recorded for not delivering all 
intervention elements was adherence having improved 
during follow-up sessions, without additional issues to 
address, or because the action or coping plans made 
during the previous intervention session remained 
relevant and did not need to be completed again.
There were 634 (95·6%) of 663 completed follow-up 
viral load measurements and 29 (4·4%) of 663 missing 
values, which were not associated with group assignment 
or viral load values at other timepoints in logistic 
regression models. Missing data were assumed to be 
missing at random, except for two patients who dropped 
out of care, discontinued medication after the second 
follow-up visit, and did not provide a viral load at the third 
visit. Because AIMS should reduce such non-persistence,3 
and non-persistence affects the dependent variable, these 
AIMS group (n=109) Treatment-as-usual 
group (n=112)
Female 14 (13%) 22 (20%)
Age (years; mean [SD]) 45·4 (11·0) 43·3 (10·8)
Ethnic origin
White 81	(74%) 62 (55%)
Sub-Saharan African 16 (15%) 21 (19%)
Caribbean* 9	(8%) 21 (19%)
Other 3 (3%) 8	(7%)
Education†
Less than or equivalent of primary education, 
lower secondary education
47 (43%) 45 (40%)
Higher secondary education, lower vocational 
education
40 (37%) 39 (35%)
Higher vocational education, university 22 (20%) 28	(25%)
Sexual orientation
Homosexual 56 (51%) 63 (56%)
Bisexual 11 (10%) 11 (10%)
Heterosexual 42 (39%) 38	(34%)
Treatment status
Treatment-experienced 52	(48%) 57 (51%)
Treatment-naive 57 (53%) 55 (49%)
CD4 cell count (cells per µL)
Treatment-experienced patients 520·6 (212·9) 535·1 (226·4)
Treatment-naive patients 379·1 (239·5) 431·8	(200·5)
Plasma HIV-RNA (copies per mL; meanlog [SD])
Treatment-experienced patients 1·74 (0·61) 1·83	(0·83)
Treatment-naive patients 4·83	(0·71) 4·30 (1·01)
Data are n (%) unless otherwise specified. AIMS=Adherence Improving self-Management Strategy. *Surinamese, 
Latin American, and Antillean. †Categorisation based on the Dutch education system.
Table 1: Baseline characteristics of the intention-to-treat population
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data cannot be treated as missing at random. Based on 
clinical advice, the two missing values were replaced by 
the median baseline viral load (50 123 copies per mL) and 
CD4 cell count (400 cells per µL) of the treatment-naive 
patients participating in the study. These decisions were 
based on consensus between team members (MdB, WV, 
and JMP) masked to group assignment.
Since all 221 patients provided data for at least one follow-
up measure, the mixed-effects analyses include the full 
intent-to-treat sample. The main treatment effects are 
described here (the results on the covariates and 
exploratory subgroup analyses are in the appendix). The 
three-level mixed-effects regression model showed that 
there was no indication of a change in the intervention 
effect across the three follow-up timepoints (time-by-
group interaction F[2409]=0·75, p=0·47). We could 
therefore examine the between-group contrast across the 
three follow-up time points, which showed that the 
intervention was effective (F[1196]=6·40, p=0·012), while 
controlling for baseline viral load, treatment experience, 
and ethnic group. Across the three timepoints (months 5, 
10, and 15), log viral load was 1·26 times higher (95% CI 
1·04–1·52) in the treatment-as-usual group (estimated 
marginal mean 44·5 copies per mL [95% CI 35·5–55·9]) 
than in the AIMS group (estimated marginal mean 
35·4 copies per mL [29·9–42·0]). There was no significant 
variability of the treatment effect across nurses (p=0·14). 
The three-level mixed-effects logistic regression model 
with detectable versus undetectable viral loads showed 
the same pattern (χ² [df=1] 3·66, p=0·056). Overall, 
patients in the treatment-as-usual group had a 1·89 times 
higher odds of a detectable viral load across the three 
timepoints, although this was not significant (95% CI 
0·98–3·65). The two-level logistic regression model of 
treatment failure indicated a significant group difference 
(χ² [df=1] 5·61, p=0·012). The odds of treatment failure 
were 2·99 times higher in treatment as usual (95% CI 
1·21–7·38).
The model examining the effects on CD4 cell 
count revealed a significant time-by-group interaction 
(F[2398]=3·09, p=0·047). We therefore examined the 
group difference for each follow-up timepoint separately. 
At the first follow-up visit, there was a non-significant 
increase in CD4 cell count in AIMS compared with 
treatment as usual (31 cells per µL, 95% CI –8·37 to 70·37); 
at the second follow-up visit the treatment-as-usual group 
caught up (–6·55 cells per µL, 95% CI –46·03 to 32·92); 
and at the third follow-up visit CD4 cell counts continued 
to rise in AIMS but not in treatment as usual, with a 
significant difference (39·39 cells per µL, 95% CI 
0·10–78·67). Marginal group means and risks for these 
analyses are in table 2.
In the base-case cost-effectiveness analysis, the Markov 
model estimated that AIMS reduced lifetime societal 
costs by €592 per patient and increased QALYs by 0·034 
per patient. AIMS was therefore cost-saving (ie, more 
QALYs and less costs) in the base case. Results were 
similar for the other scenarios and for the sensitivity 
analyses with a health-care perspective, and a 10-year 
time horizon (table 3).
Discussion
To our knowledge, this is the first randomised controlled 
trial of an HIV treatment adherence intervention that 
showed a clinically meaningful effect on viral load as 
well as cost-effectiveness. The economic model showed 
that AIMS is dominant to treatment as usual, both 
cheaper and more effective, regardless of the time 
AIMS Treatment as usual
Viral load (copies per mL) 35·4 (29·9–42·0) 44·5 (35·5–55·9)
Viral load (% detectable) 9·6 (3·8–15·4) 16·7	(8·2–25·3)
Treatment failure (%) 9·0 (2·4–15·7) 22·8	(11·7–34·0)
CD4 cell count at first 
follow-up (cells per µL)
550·9 (520·4–581·4) 519·9	(489·3–550·5)
CD4 cell count at second 
follow-up (cells per µL)
562·5 (531·7–593·3) 569·0	(538·7–599·4)
CD4 cell count at third 
follow-up (cells per µL)
597·8	(567·1–628·5) 558·4	(528·2–588·6)
Data are marginal risk (95% CI) for detectable viral load and treatment failure, and 
marginal means (95% CI) for all other variables. For CD4 cell counts, analysis was 
done per timepoint given the significant time-by-group interaction during the 
three follow-up measures (ie, effects were different at different follow-up 
timepoints). AIMS=Adherence Improving self-Management Strategy.
Table 2: Estimated marginal means and risks for viral load and CD4 cell 
count values
Lifetime 
costs
Lifetime 
QALYs
ICERs
Offset: linear decrease of AIMS effect over 18 months
Scenario 1 (base case) €–592 0·034 AIMS dominant
Scenario 2 €–843 0·036 AIMS dominant
Scenario 3 €–412 0·025 AIMS dominant
Offset: effect of AIMS maintained over another 18 months
Scenario 1 €–793 0·046 AIMS dominant
Scenario 2 €–1117 0·049 AIMS dominant
Scenario 3 €–599 0·035 AIMS dominant
Offset: no effect after stopping AIMS
Scenario 1 €–375 0·023 AIMS dominant
Scenario 2 €–546 0·024 AIMS dominant
Scenario 3 €–221 0·016 AIMS dominant
Sensitivity analyses (base case)
Healthcare 
perspective
€–597 0·034 AIMS dominant
10-year time horizon €–643 0·028 AIMS dominant
Data from base case analyses and sensitivity analyses. Scenario 1: all relative risks 
where at least five transitions occurred. Scenario 2: all available transition 
probabilities irrespective of the number of transitions. Scenario 3: only relative 
risks with at least ten transitions in total. QALY=costs per quality-adjusted 
life-years. AIMS=Adherence Improving self-Management Strategy. 
ICER=incremental cost-effectiveness ratio.
Table 3: Lifetime costs per patient, QALYS, and incremental 
cost-effectiveness ratios of AIMS compared with treatment as usual
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horizon (lifetime or 10 years) and perspective (health 
care or societal). These results were obtained in a 
heterogeneous sample of HIV-infected patients and HIV 
clinics, where AIMS was delivered by nurses as part of 
routine care.
A Cochrane review15 did not identify trials with a low 
risk of bias that showed an effect of HIV treatment 
adherence interventions on adherence and clinical 
outcomes in high-income settings. Short follow-up 
periods (<6 months) and a high risk of bias were 
important reasons for excluding many trials from these 
analyses. In the design of the current study, we tried to 
overcome these and other challenges by designing a 
study with a long follow-up (15 months), extensive efforts 
to minimise the risk of bias (which is particularly 
challenging in behavioural trials because masking to 
treatment assignment is typically not possible), and the 
detailed reporting of treatment as usual provided to 
participants.11,12,20,23 Although one limitation of our study 
was the low uptake of MEMS monitoring in the 
treatment-as-usual group, precluding meaningful 
secondary adherence analyses, the effects of AIMS on 
adherence had already been shown in two previous 
studies.17,18 Moreover, because there was no other 
plausible pathway to improved viral loads in the AIMS 
group than through improved adherence, this limitation 
did not influence the overall study conclusions. Second, 
although dropout rates were low, a 60% study refusal rate 
could have restricted the generalisability of the findings. 
We did not, however, find demographic or clinical 
differences between participants and patients who 
refused to participate in the study. Most reasons for study 
refusal (figure) are unlikely to be a barrier to the uptake 
of AIMS in routine care. Specifically with regard to 
patients’ willingness to use an electronic adherence 
monitor, we expect substantially fewer issues when 
AIMS is implemented in routine care, since patients 
know they will receive AIMS and the feedback, AIMS can 
be presented as evidence-based care, and ongoing 
technological developments will make more user-friendly 
devices available shortly. Indeed, in a pharmacy-based 
HIV treatment adherence clinic in Lausanne 
(Switzerland) that uses MEMS monitoring in routine 
care, refusal of MEMS monitoring is rare in patients in 
need of adherence support (personal communication 
with M P Schneider, University of Geneva and University 
of Lausanne).  
Similarly, findings from a recent systematic review 
identified an absence of evidence on the cost-effectiveness 
of HIV treatment adherence interventions, because it 
identified only one cost-effective HIV treatment adherence 
intervention assessed in a randomised clinical trial and 
subjected to a high-quality economic assess ment.16 
However, the study did not report evidence of intervention 
effectiveness, or the content of the control and experimental 
inter ventions, so generalisability, replicability, and 
scalability of the intervention were unclear.16 In our study, 
the aim was to obtain and report this information, and do 
a similarly high-quality economic evaluation. Given the 
absence of a suitable and up-to-date Markov model for that 
purpose, we developed a new model using ISPOR-SMDM 
guidelines.26 Up-to-date cohort data (2008–15) from all 
registered HIV patients in the Netherlands meeting our 
inclusion criteria were used to describe the natural course 
of illness. Besides effects on costs (health care and 
productivity) and quality of life, the model also incorporated 
HIV transmissions avoided, given the evidence that lower 
viral loads reduce transmission risk.2,8 Although a 
limitation of the current model was the absence of trial 
data to populate the full health state transition matrix, the 
finding that AIMS was more effective and saves resources 
was robust because all scenarios and sensitivity analyses 
produced the same result.
The cumulative results of our multicentre trial and the 
previous pilot study and single-centre trial show that AIMS 
requires few resources, is feasible to deliver in routine 
care, and is acceptable to health-care providers and patients 
(although more patient-friendly electronic monitoring 
devices are desirable). Moreover, they showed relevant and 
replicable effects of AIMS on adherence (in the pilot study 
and single-centre trial) and viral load (in the single-centre 
and multicentre trials).17,18 On average patients receiving 
treatment as usual had a 1·26 higher log viral load than 
AIMS patients, and AIMS reduced the risk of treatment 
failure (two consecutive detectable viral loads) by 61% 
(22·8% vs 9·0%). These effects were similar for treatment-
naive and treatment-experienced patients at-risk for viral 
rebound (appendix), and despite some risk of con-
tamination and the medium-to-high-quality treatment-as-
usual adherence support provided to the control group. 
The economic analysis showed that AIMS is dominant 
and that when the intervention is provided to 10 000 patients 
over a period of 18 months, the approximate savings would 
be €5 920 000 while 340 QALYs would be gained. Because 
these results have been obtained in a heterogeneous 
sample of patients and clinics, we would expect at least 
similar effects if AIMS was rolled out nationally in the 
Netherlands, and in other countries where HIV care is 
organised in a similar manner (ie, western Europe). 
Nationwide training of health-care professionals, re-
imbursement of electronic monitors, and adoption of 
AIMS in national HIV-treatment guidelines in the 
Netherlands is currently being negotiated as a first step.
In conclusion, our pragmatic, randomised controlled 
trial and economic model showed that AIMS was feasible 
to deliver in routine care, reduced viral load, increased 
QALYs, and saved resources. To our knowledge, this is 
the first HIV treatment adherence intervention for which 
such an evidence base has been established. The AIMS 
intervention should be scalable and the results 
generalisable to the wider population of patients and 
HIV clinics—at least in high-income settings. Imple-
mentation of AIMS in routine HIV clinical care is 
therefore strongly recommended.
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